The PHLPP paradox revisited: from canonical AKT phosphatases to signaling pseudoenzymes in human disease
- 25 October 2026
- journal article
- review article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 254, 118573
Abstract
No abstract availableKeywords
This publication has 127 references indexed in Scilit:
- PHLPP is neither a Phosphatase nor a Tumor SuppressorBioEssays, 2026
- In-cell NMR spectroscopy: advancements, applications, challenges, and future directions in structural biologyMagnetic Resonance Materials in Physics, Biology and Medicine, 2025
- Pathophysiologie der PostreanimationserkrankungMedizinische Klinik - Intensivmedizin und Notfallmedizin, 2025
- Ferroptosis in liver fibrosis and its potential intervention strategyCell Biology and Toxicology, 2025
- Differential efficacy of two small molecule PHLPP inhibitors to promote nucleus Pulposus cell healthJOR SPINE, 2023
- Phlpp1 Expression in Osteoblasts Plays a Modest Role in Bone HomeostasisJBMR Plus, 2023
- PROTACs: A novel strategy for cancer drug discovery and developmentMedcomm, 2023
- Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implicationsMedcomm, 2023
- Phlpp inhibitors block pain and cartilage degradation associated with osteoarthritisJournal of Orthopaedic Research, 2017
- Increased levels of the Akt-specific phosphatase PH domain leucine-rich repeat protein phosphatase (PHLPP)-1 in obese participants are associated with insulin resistanceDiabetologia, 2011